Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study [0.03%]
伊布替尼联合벤妥昔单抗治疗复发/难治慢性淋巴细胞白血病的疗效和安全性：一项II期临床研究
Mahesh Swaminathan,Alessandra Ferrajoli,Philip A Thompson et al.
Mahesh Swaminathan et al.
We explored the efficacy of the combined ibrutinib + venetoclax in patients with R/R CLL. This phase 2 study enrolled 80 patients between July 2016 and September 2018. Patients received ibrutinib for the first 3 cycles, followed by ibrutini...
Correction: Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia [0.03%]
关于遗传祖先在T细胞急性淋巴细胞白血病基因组学和生存结果方面的影响的更正通知
Haley Newman,Shawn H R Lee,Petri Pölönen et al.
Haley Newman et al.
Published Erratum
Blood cancer discovery. 2026 Feb 12:OF1. DOI:10.1158/2643-3230.BCD-25-0464 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents [0.03%]
用于治疗急性髓系白血病的维奈克拉和低甲基化药物的预后模型结合突变和细胞遗传学特征
Dimitrios Drekolias,Fatima Tuz Zahra,Caroline Fileni et al.
Dimitrios Drekolias et al.
Venetoclax (VEN) combined with hypomethylating agents (HMA) improves outcomes for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, yet overall survival (OS) remains variable. We analy...
Remodeling of Mitochondrial Networks: Cellular Adaptation and Microenvironmental Reprogramming in Hematologic Malignancies [0.03%]
血液系统恶性肿瘤中线粒体网络的重塑：细胞适应与微环境重编程
Yutang Li,Xinting Hu,Xiangxiang Zhou
Yutang Li
Mitochondria regulate critical cellular processes beyond energy production, including organelle quality control, programmed cell death, and intercellular and interorganellar communication. In hematologic malignancies, mitochondria undergo a...
Kevin C Miller,Saad Z Usmani
Kevin C Miller
First-line multiple myeloma treatment has evolved from melphalan-prednisone to quadruplet regimens incorporating proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and autologous stem cell transplantation, yield...
Bisi Miao,Jian Xu
Bisi Miao
Cancer cells display extensive heterogeneity that influences therapy response and clinical outcome, yet the underlying mechanisms remain incompletely understood. Recent studies reveal that the developmental state and molecular plasticity of...
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations [0.03%]
从生物学到临床：免疫联合疗法指导下的多发性骨髓瘤治疗新思考
Annamaria Gullà,Madhav V Dhodapkar,Hermann Einsele et al.
Annamaria Gullà et al.
The standard of care for multiple myeloma has rapidly evolved to include immune-based therapies. However, achieving durable immune control and long-term survival, particularly in high-risk patients, remains difficult. In this article, we re...
Joseph M Rocco,Nirali N Shah
Joseph M Rocco
Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a complication seen in patients receiving chimeric antigen receptor (CAR) T cells, more frequently in those with CD22- or BCMA-targeted constructs ...
Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma models [0.03%]
内源性CD28驱动多发性骨髓瘤和淋巴瘤模型CAR-T细胞持续活化
Mackenzie M Lieberman,Jason H Tong,Nkechi U Odukwe et al.
Mackenzie M Lieberman et al.
Chimeric antigen receptor (CAR) T cell therapy has reshaped the therapeutic landscape for multiple myeloma (MM), yet most patients treated with BCMA-targeted CAR T cells experience disease relapse. Consequently, we sought to determine if in...
Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia [0.03%]
基因组决定因子的纳入可提高寡核苷酸慢性粒单核细胞白血病诊断准确度
Guillermo Montalban-Bravo,Chong Wu,Juan Jose Rodriguez-Sevilla et al.
Guillermo Montalban-Bravo et al.
Recent updates to monocyte count thresholds recognize oligomonocytic chronic myelomonocytic leukemia (OM-CMML) as an early form of CMML. However, the clinical validity of these changes remains uncertain without incorporating biological and ...